GlobeNewswire (press release) ... Dr. Schaible's group designed and conducted the SONIC trial in Crohn's disease, a major clinical trial published in the New England Journal of Medicine, demonstrating the superiority of REMICADE® versus a conventional immunomodulator (azathioprine) ... and more »
Jerusalem Post A new Israeli study, published today in the prestigious journal of the American Association for the Advancement of Science, Science Translational Medicine, has discovered the working of this mechanism and proven that treatment with the immunomodulator ...
The Herald | HeraldOnline.com Teva's and Active Biotech's laquinimod (ABR-215062) is a synthetic, once-daily, orally-administered immunomodulator under investigation for the treatment of RRMS. It is related to, but chemically distinct from, linomide (Roquinimex; Active Biotech); ... and more »
Marketwire (press release) ... colitis and when there is an ongoing debate on the advantage of identifying specific Crohn's disease patients that will benefit from induction therapy with early anti-TNF therapy (top-down) rather than with steroids and immunomodulator (step-up ... and more »
GlobeNewswire (press release) ... Dr. Schaible's group designed and conducted the SONIC trial in Crohn's disease, a major clinical trial published in the New England Journal of Medicine, demonstrating the superiority of REMICADE® versus a conventional immunomodulator (azathioprine) ... and more »
4-traders (press release) One of the company's most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and non-small cell lung cancer. The cell-based cancer therapy MGN1601 for the treatment of ...
